Last updated November 2, 2026 · Reviewed by the Gala Health team
How each form is absorbed
Oral estradiol is swallowed, absorbed through the gut, and passes through the liver before most of it reaches the rest of the body. Transdermal estradiol is released continuously from an adhesive patch and moves across intact skin into the blood.
The prescribing information for Climara, a once-weekly estradiol patch, describes the difference directly. It states that the systemic availability of estradiol after transdermal administration is about 20 times higher than after oral administration, and attributes this to the absence of first pass metabolism when estradiol is given through the skin. Patch strengths are labeled in fractions of a milligram per day, while tablets are labeled in whole milligrams.
Climara also reports that the patch gives sustained estradiol levels across a 7-day wear period, and that estrogens are metabolized mainly in the liver once they are in the blood.
Dosing forms on the labels
The labels show how different the two formats are to use day to day.
| Oral estradiol tablets | Climara estradiol patch | |
|---|---|---|
| Strengths on the label | 0.5, 1 or 2 mg of micronized estradiol per tablet | Patches release 0.025, 0.05 or 0.1 mg of estradiol per day |
| How often | Taken by mouth daily | One patch applied to the skin once weekly |
| Usual starting point on the label | Usual initial dosage range of 1 to 2 mg of estradiol daily, adjusted to symptoms | Start with 0.025 mg per day for vasomotor symptoms, then adjust to response |
| Where it goes | Swallowed | Lower abdomen or upper buttock, rotating sites, never on or near the breasts |
| Review | Reevaluate periodically, with tapering attempts every 3 to 6 months | Attempt to taper or discontinue every 3 to 6 months |
Other patch brands exist and may be changed on a different schedule. Strengths, wear time, and starting doses differ by product, so follow the label and your prescriber's instructions rather than this table. The oral label we reviewed is an estradiol tablets USP label in an older format.
Both labels give the same overall instruction: use the lowest effective dose for the shortest duration consistent with treatment goals and risks for the individual woman. If you have a uterus, the labels say a progestin or progestogen should also be considered to reduce the risk of endometrial cancer. See our guide to progesterone for sleep and uterine protection.
What the labels and The Menopause Society say about clot risk
Labels for oral and patch estrogens both carry warnings about blood clots, and both are based on the Women's Health Initiative (WHI). The WHI tested one oral product, conjugated estrogens at 0.625 mg daily, alone or with medroxyprogesterone acetate, in women aged 50 to 79. The Climara label states that only this oral dose was studied, so the relevance of the WHI findings to lower doses, other routes of administration, or other estrogen products is not known, and that without such data these risks cannot be definitively excluded for other products.
The oral estradiol label similarly says that other doses and dosage forms were not studied in the WHI and that, without comparable data, the risks should be assumed to be similar. So the product labels do not claim that a patch is safer. They tell prescribers not to assume a difference either way.
The Menopause Society (formerly the North American Menopause Society) goes a step further. Its 2022 hormone therapy position statement highlights that transdermal routes of administration and lower doses of hormone therapy may decrease the risk of venous thromboembolism and stroke. The word is "may": this is a statement about likelihood from the research available at the time, not a guarantee for any one person, and the statement lists route as one of several factors that shape risk, alongside type, dose, duration, timing of initiation, and use of a progestogen.
The same statement says benefits outweigh risks for most healthy symptomatic women who are younger than 60 and within 10 years of menopause onset, and that risk stratification by age and time since menopause is recommended.
Side effects that differ by format
The Climara label lists breast pain, upper respiratory tract infection, headaches, abdominal pain, pain, and edema as its most common adverse reactions (10 percent or more in trials), and its postmarketing list includes application site reactions. A patch that does not stay on, or skin that reacts to adhesive, is a practical limit for some people.
The oral estradiol label lists nausea, vomiting, abdominal cramps, and bloating among reported reactions, along with breast tenderness. For the full picture of both, including boxed warnings, read our guide to HRT side effects.
Who might prefer each
There is no single right answer, and the choice is clinical. These are the questions a provider usually weighs:
- Clot or stroke risk factors: because The Menopause Society notes transdermal routes may lower that risk, the patch is often discussed first for people with such factors. Your provider decides whether either form is appropriate at all.
- Daily routine: a pill is a daily habit; a weekly patch is a weekly one. Some people prefer not to think about it every day, others do not want anything on their skin.
- Skin and adhesion: sweating, tight waistbands, swimming, or skin that reacts to adhesive can make a patch harder to keep on.
- How you respond: dose adjustment is normal with either form, and the labels build in reassessment every few months.
Only a clinician who knows your history can say whether estrogen is appropriate. Estrogen labels carry contraindications and boxed warnings, so your history needs to be reviewed first.
How it works at Gala
At Gala, you complete an online intake and a licensed provider reviews it. If hormone therapy is appropriate, the provider prescribes it, and the options include estradiol as a pill or a patch, along with progesterone, vaginal estradiol, and non-hormonal options. No insurance is required, your care team is available by message to adjust your dose, and medication ships to your home.
Read more about estradiol at Gala, see how perimenopause differs from menopause, or browse the hormone health hub. Ready to see whether you qualify? Start your online menopause assessment.
Frequently asked questions
Is the estradiol patch safer than the pill?
The product labels do not say so. They state that the Women's Health Initiative studied only one oral dose, and that risks for other doses and routes cannot be excluded. The Menopause Society's 2022 position statement says transdermal routes and lower doses may decrease the risk of venous thromboembolism and stroke. A provider weighs this against your own history.
Why is the patch dose so much smaller than the pill dose?
A patch delivers estradiol through the skin and avoids first pass metabolism in the liver. The Climara label states that systemic availability of estradiol after transdermal use is about 20 times higher than after oral use, so patch strengths are listed in fractions of a milligram per day.
How often do I change an estradiol patch?
It depends on the product. Climara is applied once weekly, to the lower abdomen or upper buttock, and the site is rotated. Other brands may be changed more often, so follow the instructions on your own prescription.
Do I need progesterone with either one?
If you have a uterus, the labels say adding a progestogen should be considered to reduce the risk of endometrial cancer from estrogen alone. A woman without a uterus generally does not need one. Your provider will tell you which applies to you.
Can I switch from the pill to the patch or the other way around?
Switching is a decision for you and your provider, who will choose a starting dose and reassess how you feel. Do not change forms or doses on your own.
Ready to talk to a provider?
Your answers go to a licensed provider, who decides whether treatment is right for you. Learn more about Hormone Health.
Sources
- Bayer HealthCare. Climara (estradiol transdermal system) prescribing information. NLM DailyMed.
- ANI Pharmaceuticals. Estradiol Tablets, USP prescribing information (Northwind Health listing). NLM DailyMed.
- The North American Menopause Society. The 2022 hormone therapy position statement: press release with highlights. 2022.
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
This article is for general information and is not medical advice. Talk to a licensed provider about your own health.